Literature DB >> 23564578

Complement in immune and inflammatory disorders: therapeutic interventions.

Daniel Ricklin1, John D Lambris.   

Abstract

With the awareness that immune-inflammatory cross-talk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. Although prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, in this review we discuss complement-directed therapeutic concepts and highlight promising candidate molecules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564578      PMCID: PMC3623010          DOI: 10.4049/jimmunol.1203200

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

Review 1.  Paul Ehrlich: magister mundi.

Authors:  Jürgen Drews
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

2.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

3.  Protective effects of C5a blockade in sepsis.

Authors:  B J Czermak; V Sarma; C L Pierson; R L Warner; M Huber-Lang; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

4.  TP-10 (AVANT Immunotherapeutics).

Authors:  P Rioux
Journal:  Curr Opin Investig Drugs       Date:  2001-03

5.  Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.

Authors:  Carl Atkinson; Hongbin Song; Bo Lu; Fei Qiao; Tara A Burns; V Michael Holers; George C Tsokos; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

6.  Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Peter Hillmen; Stephen J Richards; Dupe Elebute; Judith C Marsh; Jason Chan; Christopher F Mojcik; Russell P Rother
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

7.  A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.

Authors:  Joshua M Thurman; Damian M Kraus; Guillermina Girardi; Dennis Hourcade; Hee J Kang; Pamela A Royer; Lynne M Mitchell; Patricia C Giclas; Jane Salmon; Gary Gilkeson; V Michael Holers
Journal:  Mol Immunol       Date:  2005-01       Impact factor: 4.407

Review 8.  Targeting anticomplement agents.

Authors:  R A Smith
Journal:  Biochem Soc Trans       Date:  2002-11       Impact factor: 5.407

9.  Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.

Authors:  Edward D Verrier; Stanton K Shernan; Kenneth M Taylor; Frans Van de Werf; Mark F Newman; John C Chen; Michel Carrier; Axel Haverich; Kevin J Malloy; Peter X Adams; Thomas G Todaro; Christopher F Mojcik; Scott A Rollins; Jerrold H Levy
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  The proinflammatory mediators C3a and C5a are essential for liver regeneration.

Authors:  Christoph W Strey; Maciej Markiewski; Dimitrios Mastellos; Ruxandra Tudoran; Lynn A Spruce; Linda E Greenbaum; John D Lambris
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  108 in total

1.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

2.  TMA: beware of complements.

Authors:  Daniel Ricklin; Douglas B Cines
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

3.  Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health.

Authors:  Cynthia Owsley; Carrie Huisingh; Gregory R Jackson; Christine A Curcio; Alexander J Szalai; Nassrin Dashti; Mark Clark; Kia Rookard; Mark A McCrory; Tyler T Wright; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Gerald McGwin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

Review 4.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

5.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

Review 6.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

Review 7.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

8.  Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2015 Jun-Jul       Impact factor: 4.565

9.  Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.

Authors:  Tomoki Maekawa; Toshiharu Abe; Evlambia Hajishengallis; Kavita B Hosur; Robert A DeAngelis; Daniel Ricklin; John D Lambris; George Hajishengallis
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

10.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.